Cannabis spending is on the rise in Canada. On Thursday (January 25), Statistics Canada revealed Canadians spent approximately $5.7 billion in medical and non-medical last year.
The government agency presented the results from surveys it conducted among the Canadian population, stating that 4.9 million Canadians between the ages 15 and 64 admitted to spending money for cannabis last year. “This was equivalent to around $1,200 per cannabis consumer,” the agency said.

Population of users increases in 45+ age group

While it might be surprising, cannabis spending isn’t limited to the younger population. As the agency states,  “The share of consumption among 45- to 64-year-olds (the oldest age group in the study) has been increasing in recent years. In 2017 this particular demographic accounted for 23 percent of the user population.
Data shows the vast majority of reported Canadian households spending money on cannabis products were intended for recreational purposes. The agency indicated marijuana spending has been on an annual six percent increase since it started tracking this statistic in 1961.
As part of their revamped effort on cannabis data collection, Statistics Canada launched a new hub meant to provide data on topics like health, economy, and prices.
Domestically produced cannabis resulted in sales of $5.4 billion, while international product accounted for $300 million in sales during 2017.


aurora-cannabisInvestor Takeaway

The availability of this type of information could better prepare investors when it comes to making picks in the public market. Additionally, companies employing some form of advanced data like this would help to paint a clearer picture of the available market in Canada.
Case in point, Statistics Canada also revealed it will be developing new data sources and working to improve the methods by which it collects this information. As the cannabis industry continues to grow it will be key for the agency to keep track of figures and estimations from the consuming population.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less